大胆的惜珊
Lv1
30 积分
2023-08-30 加入
-
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
5天前
已完结
-
Comprehensive analysis of kinase inhibitor selectivity
5天前
已完结
-
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile
20天前
已完结
-
Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
30天前
已完结
-
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
1个月前
已完结
-
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
1个月前
已完结
-
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
2个月前
已完结
-
The nuclear cytokine IL-37a controls lethal cytokine storms primarily via IL-1R8-independent transcriptional upregulation of PPARγ
2个月前
已完结
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
-
Understanding the impact of psychosocial working conditions on workers’ health: we have come a long way, but are we there yet?
2个月前
已完结